This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Discovery Labs Presents Final Assessment In A Series Of Pharmacoeconomic Analyses That Explore Impact Of Reintubation On Healthcare Costs

WARRINGTON, Pa., June 11, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced the presentation of the last in a series of pharmacoeconomic analyses indicating that a reduction in the rate of reintubation among preterm infants may potentially result in hospital cost-savings related to fewer reintubation-related diagnoses of bronchopulmonary dysplasia (BPD), air leak, sepsis, necrotizing enterocolitis (NEC), or intraventricular hemorrhage (IVH), including savings of up to $562,000 per 100 patients diagnosed with BPD.  The pharmacoeconomic model was developed using an observation from a previously published study that preterm infants who receive SURFAXIN® may have lower rates of reintubation when compared with preterm infants who received either Curosurf® or Survanta®. 

The findings from this third and final pharmacoeconomic analysis were presented recently at the 2013 Pediatric Pharmacy Advocacy Group (PPAG) Annual Meeting held in Indianapolis, IN.

Inpatient hospital costs for treating neonates with the primary diagnoses of BPD, air leak, sepsis, NEC, or IVH was obtained from a 2009 database of more than seven million U.S. hospital discharges, and multiplied by the intubation rate observed in each surfactant treatment group and the incidence of each morbidity in reintubated infants.  The model compared projected costs between the SURFAXIN treatment group and the comparator surfactant treatment groups from two phase 3 trials, SELECT and STAR, and yielded potential differences in hospital costs per 100 patients ranging from $34,000 for air leak alone to $562,000 for BPD (Figure 1).

(Photo: http://photos.prnewswire.com/prnh/20130611/NY29795 )

Discovery Labs expects to submit this analysis to a peer-reviewed, neonatology-focused medical journal later this year.

"A substantial proportion of infants with RDS, especially those under 1,000 grams, need to be reintubated.  The occurrence of major morbidities associated with reintubation in preterm children may potentially have a profound impact on healthcare resource utilization in the neonatal population," said Fernando R Moya, MD, SELECT Trial Principle Investigator and Director of Neonatology at New Hanover Regional Medical Center, Wilmington, NC. "Lower reintubation rates such as those observed with SURFAXIN therapy may significantly lower in-hospital costs for the treatment of reintubated infants."

The series of pharmacoeconomic analyses is based on the observations reported in the first ever, full description of the consequences of reintubation in preterm neonates published in the Journal of Neonatal- Perinatal Medicine (Volume 4, Number 2, 2011).   Those observations include:

  • Infants who were successfully extubated and did not require reintubation had a significantly lower mortality rate compared with infants who subsequently required reintubation (0.5 percent vs. 18 percent, respectively p<0.05).
  • Infants who required reintubation had significantly higher rates of major complications of prematurity, including BPD, air leak, sepsis, NEC and IVH.
  • Infants treated with SURFAXIN demonstrated a significantly lower reintubation rate compared with infants treated with animal-derived surfactants Curosurf (33 percent vs. 47 percent respectively; p<0.05) and Survanta (35 percent vs. 43 percent respectively; p<0.05).
  • Infants treated with SURFAXIN demonstrated a significantly higher combined outcome of survival without reintubation compared with those infants treated with animal-derived surfactants Curosurf (67 percent vs. 53 percent respectively; p<0.05) and Survanta (65 percent vs. 57 percent respectively; p<0.05).

The first published pharmacoeconomic analysis suggested that the lower rate of reintubation resulted in a potential decrease in direct hospital expenses of approximately $160,000 to $252,000 per 100 infants when compared with infants treated with Curosurf and Survanta based solely on the need for extended time on mechanical ventilation due to reintubation.  Authors in that analysis noted that additional analyses investigating potential reduction in other reintubation-associated morbidities were warranted. 

The second pharmacoeconomic analysis in the series suggested that the reduced rate of BPD related to reintubation might also result in an average potential hospital cost savings of $389,247 per 100 infants. 

This study presented at the PPAG annual meeting is the third and final pharmacoeconomic analysis and includes a further analysis related to BPD, as well as other key morbidities such as air leak, IVH, NEC and sepsis.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs